AboutCompany Overview

Viventia Bio is developing next generation oncology therapeutics utilizing our proprietary Targeted Protein Therapeutic technology (TPT). Our novel TPTs have been designed to overcome the efficacy and safety challenges of existing antibody-drug conjugates.

With over 40 publications, 130 patents and two advanced product candidates, one currently in Phase III and the other expected to enter Phase III in 2016, we are committed to designing, engineering, developing and commercializing TPTs to identify and address patients with cancers that have a high unmet medical need. Our business model is to both develop proprietary products as well as utilize collaboration to develop leading product candidates.

Viventia possesses laboratories and fully integrated GMP manufacturing facilities, ensuring robust and cost-effective production. Viventia has attracted seasoned biopharma leaders and Board members, and has established a strong network of scientific advisors and leading specialists in discovery, translational medicine, and cancer drug development.